Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307

Saved in:
Bibliographic Details
Published in:Rare Cancers and Therapy
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867301675312611328
collection WordPress RSS
FRELIP Feed Integration
container_title Rare Cancers and Therapy
description
discipline_display Oncology
discipline_facet Oncology
format Online Article
RSS Article
genre Journal Article
id rss_article:61397
institution FRELIP
journal_source_facet Rare Cancers and Therapy
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
Oncology
General
Oncology
sub_discipline_display General
sub_discipline_facet General
subject_display Oncology
General
Oncology
Oncology
General
Oncology
subject_facet Oncology
General
Oncology
title First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_auth First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_full First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_fullStr First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_full_unstemmed First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_short First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
title_sort first-line tislelizumab plus chemotherapy for advanced or metastatic squamous non-small cell lung cancer: 4-year long-term follow-up from rationale-307
topic Oncology
General
Oncology
url https://link.springer.com/article/10.1007/s40487-026-00424-z